Catalyst Biosciences (NASDAQ: CBIO) reports that it has achieved a financial milestone under its collaboration with ISU Abxis following the enrollment of the first patient in its hemophilia B clinical trial. In June 2017, the first patient and cohort were enrolled in a phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B to evaluate Catalyst’s next-generation Factor IX variant, CB 2679d/ISU304, for subcutaneous prophylaxis. ISU Abxis and Catalyst plan to have top-line data from the clinical trial by the end of 2017. “We are pleased to have achieved another financial milestone with the Factor IX clinical program, but for us the highlight of the Factor IX program has been the rapid patient enrollment in the clinical trial to date,” Catalyst president and CEO Nassim Usman, Ph.D., stated in the news release.
To view the full press release, visit: http://nnw.fm/qwl8W
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
